Product image of Eribulina Advanz Pharma (Eribulin Mesylate) supplied by GNH India

Eribulina Advanz Pharma

Active Ingredient:
Eribulin Mesylate
Origin:
EU

Eribulina Advanz Pharma (Eribulin Mesylate)

Eribulin Mesylate is a chemotherapy drug used to treat certain types of cancer. It works by slowing or stopping cancer cell growth, often prescribed for metastatic breast cancer.

Manufacturer / TM Owner

Advanz Pharma Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Eribulin Mesylate is primarily used in the treatment of metastatic breast cancer. It may also be considered for other types of cancer under medical supervision. The drug is administered intravenously and targets cancer cells to inhibit their growth.

Side Effects

  • Common effects of Eribulin Mesylate may include fatigue, nausea, and hair loss. Some patients may experience peripheral neuropathy, which can cause numbness or tingling in the hands and feet. These effects vary among individuals and should be discussed with a healthcare provider.

Precautions & Warnings

  • Eribulin Mesylate should be handled with care, as it is a potent chemotherapy agent. It is important to follow proper safety protocols when administering the drug to avoid contamination. Patients should be monitored for signs of infection or other complications during treatment.

Avoid Interactions

  • Eribulin Mesylate may interact with other medications, including those that affect liver function. It is important to inform healthcare providers about all current medications to avoid potential interactions. Alcohol consumption should be avoided during treatment.

Frequently Asked Questions

Eribulin Mesylate is primarily used to treat metastatic breast cancer and may be considered for other types of cancer under medical supervision.

Eribulin Mesylate is administered intravenously by a healthcare professional in a clinical setting.

Common side effects may include fatigue, nausea, hair loss, and peripheral neuropathy, which can cause numbness or tingling in the hands and feet.

Eribulin Mesylate may interact with other medications, so it is important to inform healthcare providers about all current medications.

Eribulin Mesylate should be handled with care, and proper safety protocols should be followed to avoid contamination. Patients should be monitored for signs of infection or other complications.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Eribulin Mesylate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT